Document is current
Any future updates will be listed below
-
Authors
Kawabata, Hiroshi https://orcid.org/0000-0002-1918-8635
Usuki, Kensuke
Shindo-Ueda, Maki
Kanda, Junya
Tohyama, Kaoru
Matsuda, Akira
Araseki, Kayano
Hata, Tomoko
Suzuki, Takahiro
Kayano, Hidekazu
Shimbo, Kei
Chiba, Shigeru
Ishikawa, Takayuki
Arima, Nobuyoshi
Nohgawa, Masaharu
Miyazaki, Yasushi
Kurokawa, Mineo
Arai, Shunya
Mitani, Kinuko
Takaori-Kondo, Akifumi
,
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H20-Nanchi-Ippan-001, H23-Nanchi-Ippan-001, H26-Nanchi-Ippan-062, H27-Nanchi-Ippan-016, H29-Nanchi-Ippan-026)
- License Information
-
More Information
Article History
Received: 9 April 2019
Revised: 12 July 2019
Accepted: 17 July 2019
First Online: 29 July 2019
Compliance with ethical standards
:
: Dr. Kawabata reports personal fees from Nippon Shinyaku Co., Ltd. outside the submitted work. Dr. Tohyama reports personal fees from Celgene Corporation and SymBio Pharmaceuticals Ltd. outside the submitted work. Dr. Matsuda reports personal fees from Kyowa Hakko Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., GlaxoSmithKline K. K., Celgene Corporation, Alexion Pharmaceuticals, Inc., Sanofi K. K., Beckman Coulter K. K., and Shire Japan K.K.; grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K. K.; and grants from Astellas Pharm Inc., Asahi Kasei Pharma Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan Inc., MSD K. K., Daiichi Sankyo Co., Ltd., Abbvie GK, and HUYA Bioscience International outside the submitted work. Dr. Suzuki reports personal fees from Novartis Pharma K.K., Nippon Shinyaku Co., Ltd., Celgene Corporation, and Kyowa Hakko Kirin Co., Ltd.; grants from Astellas Pharma Inc. outside the submitted work. Mr. Shimbo reports personal fees from Celgene Corporation, and Bristol-Myers Squibb outside the submitted work. Dr. Chiba reports grants from Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb, and Astellas Pharma Inc. outside the submitted work. Dr. Miyazaki reports personal fees from Novartis Pharma K.K., Dainippon Sumitomo Pharma Co., Ltd., Celgene Corporation, and SymBio Pharmaceuticals Ltd.; personal fees and grants from Kyowa Hakko Kirin Co., Ltd.; grants from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Seiyaku K.K. outside the submitted work. Dr. Mitani reports grants and personal fees from Kyowa-Hakko Kirin Co., Ltd.; and grants from Chugai Pharmaceutical Co., Ltd., Novartis Pharma K.K., Teijin Pharma Ltd., Japan Blood Products Organization, Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Toyama Chemical Co., Ltd. outside the submitted work. Dr. Kurokawa reports personal fees from Shionogi & Co., Ltd. and Celgene Corporation; grants from Kyowa Hakko Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Bristol-Myers Squibb, and Pfizer Seiyaku K.K. outside the submitted work. Dr. Takaori-Kondo reports personal fees from Yanssen Pharmaceutical K.K., Novartis Pharma K.K., and Bristol-Myers Squibb; personal fees and grants from Pfizer Seiyaku K.K. and Celgene Corporation; and grants from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Japan Blood Products Organization, Eisai Co., Ltd., Shionogi & Co., Ltd., Mochida Pharmaceutical Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. outside the submitted work.
